7-OH & Kratom Dependence Treatment in North Dakota

No. As of August 5, 2026, North Dakota prohibits the purchase, possession, sale, distribution, manufacture, and other specified activities involving kratom and kratom products statewide under Executive Order 2026-04.

Separately, the North Dakota Board of Pharmacy issued an emergency rule classifying 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance.

Yes. North Dakota currently prohibits the creation, manufacture, delivery, distribution, sale, purchase, and possession of kratom and kratom products under Executive Order 2026-04, which took effect at 5:00 p.m. on August 5, 2026.

There is no lawful consumer purchasing age because the emergency order prohibits these activities statewide regardless of age. A willful violation is an infraction under North Dakota law.

7-OH is already prohibited in North Dakota. It is classified as a Schedule I controlled substance under an emergency Board of Pharmacy rule, and the broader Executive Order 2026-04 prohibits kratom and kratom products generally.

Separately, the DEA announced its intent to temporarily place 7-OH above a specified threshold into Schedule I under federal law. As of the August 14, 2026 legal review date, the Federal Register listed that action as a proposed temporary-scheduling action rather than a published temporary final order. Federal status could change shortly after publication of this page.

Consider speaking with a medical provider before your supply ends, especially if you use 7-OH every day or experience withdrawal symptoms between doses.

Tell the provider the exact product you use, the amount per dose, how frequently you take it and whether you use any other substances. Avoid automatically replacing 7-OH with another concentrated or unregulated product.

There is no universal over-the-counter replacement for 7-OH.

The appropriate treatment depends on whether you were using it for pain, energy, anxiety, opioid withdrawal, cravings or to prevent withdrawal from 7-OH itself. A medical provider can evaluate the underlying reason and recommend appropriate treatment options.

Possible symptoms include restlessness, sweating, chills, body aches, nausea, stomach discomfort, diarrhea, difficulty sleeping, anxiety, irritability, low mood and cravings.

Symptoms can vary depending on the product, concentration, dose, frequency of use, length of use and other substances being taken.

There is no single established timeline that applies to every patient.

The duration and severity of withdrawal may be influenced by how much you use, how often you take it, how long you have used it, the concentration of the product, your health history and whether other substances are involved.

A provider can offer more individualized guidance after completing an evaluation.

Some people may be able to receive outpatient or telehealth support, while others require in-person detoxification or a higher level of care.

The safest setting depends on your level of dependence, withdrawal history, medical conditions, mental-health symptoms, use of other substances and available support at home.

Do not attempt to manage severe withdrawal or serious medical symptoms without professional help.

Eligible patients located in North Dakota may receive a confidential online medical evaluation from DevotedDOc when an appropriately licensed provider is available.

The provider will determine whether telehealth care is appropriate or whether you need in-person treatment or a higher level of support.

A licensed provider may consider buprenorphine/naloxone in selected cases involving opioid-like dependence or opioid use disorder.

Suboxone is not automatically appropriate for everyone using 7-OH. A medical evaluation is required, and receiving an appointment does not guarantee that a particular medication will be prescribed.

Not everyone requires residential rehabilitation.

Depending on your symptoms and treatment needs, care may be provided through telehealth, outpatient medical treatment, counseling, intensive outpatient treatment, medically supervised detoxification or residential care.

A clinical evaluation helps determine the safest and most appropriate level of support.

7-hydroxymitragynine — abbreviated 7-OH, 7OH or 7-HMG — is one of several alkaloids that occur naturally in the kratom plant, Mitragyna speciosa, though only in small amounts in raw kratom leaf.

7-OH is not the same as kratom itself. Kratom refers to the whole botanical material, which contains many alkaloids beyond 7-OH. Commercial 7-OH tablets, gummies, shots and similar products may contain added, isolated or enhanced concentrations that are substantially different from traditional kratom leaf.

Regular use may lead to tolerance and physical dependence. A person who has become dependent may experience withdrawal symptoms, cravings or difficulty reducing use.

Needing more of the product to achieve the same effect or taking it mainly to avoid feeling sick may be signs that medical support is needed. FDA has documented cases of substance-use disorder, tolerance, cravings and withdrawal associated with kratom products.

These are synthetically derived compounds related to 7-hydroxymitragynine. Under North Dakota’s current emergency order, the definition of kratom includes alkaloids or alkaloid derivatives created through chemical synthesis or biosynthetic means that synthetically alter kratom alkaloids or derivatives. These products are covered by the statewide prohibition. The DEA has also issued notices of intent to place these substances in Schedule I under federal law. Federal status may have changed since this page’s August 14, 2026 legal review date.

DevotedDOc provides private medical care through secure telehealth appointments.

Patient information is handled according to applicable privacy requirements and DevotedDOc’s published privacy practices.